These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26284387)

  • 1. [Expression and significance of CMTM5 and epidermal growth factor receptor in prostate cancer].
    Yuan YQ; Zhang YX; Liu ZH; Qin CP; Sheng ZZ; Xu T; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):571-6. PubMed ID: 26284387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM5 is reduced in prostate cancer and inhibits cancer cell growth in vitro and in vivo.
    Xiao Y; Yuan Y; Zhang Y; Li J; Liu Z; Zhang X; Sheng Z; Xu T; Wang X
    Clin Transl Oncol; 2015 Jun; 17(6):431-7. PubMed ID: 25387568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
    Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
    Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells.
    Yuan Y; Sheng Z; Liu Z; Zhang X; Xiao Y; Xie J; Zhang Y; Xu T
    J Cancer; 2020; 11(13):3762-3770. PubMed ID: 32328181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CMTM5 inhibits the tumor cell behavior of prostate cancer by downregulation of HER2].
    Xu T; Li J; Xiao YB; Liu ZH; Li Q; Wang XF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 42(4):386-90. PubMed ID: 20721248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research advances in CKLF-like MARVEL transmembrane domain containing member 5].
    Yuan YQ; Xiao YB; Liu ZH; Zhang XW; Xu T; Wang XF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2012 Dec; 34(6):625-8. PubMed ID: 23286412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced CMTM5 expression correlates with carcinogenesis in human epithelial ovarian cancer.
    Li P; Liu K; Li L; Yang M; Gao W; Feng J; Lv Y; Qu X; Kong B
    Int J Gynecol Cancer; 2011 Oct; 21(7):1248-55. PubMed ID: 21841490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitory effect of CMTM5 on xenografted human prostatic cancer in nude mice].
    Xiao YB; Xie J; Zhang GX; Li J; Hao YC; Zhang XW; Liu ZH; Xu T; Wang XF
    Zhonghua Nan Ke Xue; 2012 Mar; 18(3):195-9. PubMed ID: 22474980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances.
    Chen Z; Cui N; Zhao JS; Wu JF; Ma F; Li C; Liu XY
    Eur J Histochem; 2021 Jan; 65(1):. PubMed ID: 33478201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CMTM5 exhibits tumor suppressor activity through promoter methylation in oral squamous cell carcinoma.
    Zhang H; Nan X; Li X; Chen Y; Zhang J; Sun L; Han W; Li T
    Biochem Biophys Res Commun; 2014 May; 447(2):304-10. PubMed ID: 24721428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
    Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
    Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of polyethylenimine-functionalized gold nanoclusters carrying plasmid CMTM5 in impeding the malignant progression of prostate cancer cells by promoting EGFR endocytosis.
    Li L; Li C; Miao F; Chen W; Kong X; Ye R; Feng R
    Neoplasma; 2024 Feb; 71(1):48-59. PubMed ID: 38295104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expressions of TFF1 and TFF3 in prostate cancer and prostatic intraepithelial neoplasia and their clinical significance].
    Liu M; Jin RS
    Zhonghua Nan Ke Xue; 2015 Apr; 21(4):315-9. PubMed ID: 26027097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Abnormally lower expression of cmtm5 gene in bone marrow cells from patients with multiple myeloma].
    Niu JH; Bao L; Zhang Y; Li JL; Li LD; Xie M; Qin YZ; Lai YY; Jiang Q; Shi HL; Liu YR; Jiang B; Chen SS; Huang XJ; Ruan GR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):363-7. PubMed ID: 20416169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha.
    Guo X; Li T; Wang Y; Shao L; Zhang Y; Ma D; Han W
    Biochem Biophys Res Commun; 2009 Sep; 387(1):139-42. PubMed ID: 19577543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMTM5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway.
    Li H; Guo X; Shao L; Plate M; Mo X; Wang Y; Han W
    BMB Rep; 2010 Mar; 43(3):182-7. PubMed ID: 20356458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant expression of CKLF-like MARVEL transmembrane member 5 (CMTM5) by promoter methylation in myeloid leukemia.
    Niu J; Li H; Zhang Y; Li J; Xie M; Li L; Qin X; Qin Y; Guo X; Jiang Q; Liu Y; Chen S; Huang X; Han W; Ruan G
    Leuk Res; 2011 Jun; 35(6):771-6. PubMed ID: 21168207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association of
    Liu TF; Lin T; Ren LH; Li GP; Peng JJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 52(5):856-862. PubMed ID: 33047719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines.
    Shao L; Cui Y; Li H; Liu Y; Zhao H; Wang Y; Zhang Y; Ng KM; Han W; Ma D; Tao Q
    Clin Cancer Res; 2007 Oct; 13(19):5756-62. PubMed ID: 17908965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the leptin and leptin receptor expressions in prostate tissues.
    Hoon Kim J; Lee SY; Myung SC; Kim YS; Kim TH; Kim MK
    Asian J Androl; 2008 Nov; 10(6):923-8. PubMed ID: 18958356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.